pharma · Glaucoma · Macular Edema
Allergan Pharmaceuticals International
Allergan Pharmaceuticals International Limited
Allergan Pharmaceuticals International patent portfolio — 25 USPTO pharmaceutical patents (A61K/A61P) with grant dates, status, and loss-of-exclusivity filters.
Company details
- Status
- Public
- HQ
- Dublin, IE
- Programs
- 13
- Drugs
- 15
- Patents
- 25
Allergan Pharmaceuticals International patents
25 pharmaceutical patents indexed for Allergan Pharmaceuticals International. 0 expire within 24 months.
Allergan Pharmaceuticals International has 25 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 0 expire within 24 months — use filters for patent-cliff planning.
Patent portfolio
-
US 12383545
TREATMENT OF MIGRAINE
granted -
US 2025064788
TREATMENT OF MIGRAINE
granted -
US 2024180883
TREATMENT OF MIGRAINE
granted -
WO 2024081718
ANTAGONISTE DU RÉCEPTEUR CGRP POUR LE TRAITEMENT DE LA MIGRAINE
granted -
CA 3244873
TRAITEMENT PRÉVENTIF DE LA MIGRAINE
granted -
WO 2023077094
TRAITEMENT D'UN TROUBLE DÉPRESSIF MAJEUR
granted -
US 2023130736
METHODS OF TREATING MIGRAINE
granted -
US 2022380379
PHARMACEUTICAL COMPOUNDS
granted -
US 2022193051
TREATMENT OF MIGRAINE
granted -
US 2022031686
Treatment of Migraine
granted -
US 2021387969
BICYCLIC AZA COMPOUNDS AS MUSCARINIC M1 AND/OR M4 RECEPTOR AGONISTS
granted -
CA 3177686
COMPOSITIONS COMPRENANT DE LA TROPOELASTINE RETICULEE A DE L'ACIDE HYALURONIQUE ET LEURS PROCEDES D'UTILISATION
granted -
CA 3156009
POLYTHERAPIE AVEC DES ANTAGONISTES DU CGRP
granted -
CA 3152006
TROPOELASTINE DESTINEE A ETRE UTILISEE DANS LE TRAITEMENT DE LA CICATRISATION DE L'ACNE
granted -
WO 2021005494
ANTAGONISTES DU CGRP ET DÉRIVÉS DE CLOSTRIDIALES POUR LE TRAITEMENT DE TROUBLES NEUROPSYCHIATRIQUES ET NEUROLOGIQUES
granted -
WO 2021005497
ANTAGONISTES DU CGRP ET DÉRIVÉS DE CLOSTRIDIUM POUR LE TRAITEMENT DE TROUBLES ASSOCIÉS À LA DÉPRESSION CORTICALE ENVAHISSANTE
granted -
WO 2021005493
ANTAGONISTES DU CGRP ET TOXINES BOTULINIQUES POUR LE TRAITEMENT DE TROUBLES INFLAMMATOIRES ET NEUROLOGIQUES
granted -
US 2020345623
METHODS OF SCAR PREVENTION AND/OR TREATMENT
granted -
CA 3133787
GELS HOMOGENES INJECTABLES COMPRENANT DE MULTIPLES FORMES D'ACIDE HYALURONIQUE ET LEURS PROCEDES DE FABRICATION
granted -
WO 2020012244
TRAITEMENT DE LA RECTOCOLITE HÉMORRAGIQUE AU MOYEN DE BRAZIKUMAB
granted -
CA 3105778
POLYTHERAPIE AVEC DES ANTAGONISTES DU CGRP ET DES DERIVES DE CLOSTRIDIUM
granted -
US 2019374520
TREATMENT OF MIGRAINE
granted -
US 2019374518
TREATMENT OF MIGRAINE
granted -
CA 3091946
EXPANSION ET DIFFERENCIATION DE CELLULES SOUCHES
granted -
WO 2019016609
TRAITEMENT DE LÉSIONS NON INFLAMMATOIRES
granted
Frequently asked questions
How many patents does Allergan Pharmaceuticals International have?
25 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do Allergan Pharmaceuticals International patents expire?
0 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.